SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech vs. Shorts -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (252)11/9/1999 12:42:00 AM
From: RWReeves  Read Replies (1) | Respond to of 427
 
From the PCYC thread;

Phase II's

Pancreatic Cancer
University of Pittsburgh Enrolling patients

Pancreatic Cancer
Johns Hopkins University Oncology Center Pending

Pancreatic Cancer
University of Chicago Enrolling patients

(Current trials in Xytrin.)

RWR



To: Biomaven who wrote (252)11/15/1999 4:13:00 PM
From: Vector1  Read Replies (1) | Respond to of 427
 
Guess who Avalon has added to thier short list.
IDPH. I just saw a summary but the concern is flatening of rev growth. Although I am long (very long) CLTR I think Rit is a great drug with potential beyond NHL. IDPH/DNA is going to present a huge number of abstracts at ASH. I wouldn't bet against them.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News